Kolon Life Science Inc. (KOSDAQ:102940)
South Korea · Delayed Price · Currency is KRW 14,560
-140 (-0.95%)
Sep 3, 2026, 3:30 PM KST
Kolon Life Science Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 190,599 | 667,298 | 285,738 | 293,298 | 312,699 | 493,057 | |
Market Cap Growth | -47.19% | 133.53% | -2.58% | -6.20% | -36.58% | 48.78% |
Enterprise Value | 316,237 | 782,098 | 384,979 | 380,259 | 385,923 | 578,014 |
Last Close Price | 14560.00 | 51700.00 | 23000.00 | 25700.00 | 27400.00 | 43250.00 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 6.06 | 26.73 | - | - | 146.58 | - |
Forward PE | - | 30.73 | 30.73 | 30.73 | 30.73 | 30.73 |
PS Ratio | 0.90 | 3.19 | 1.77 | 2.35 | 1.94 | 2.98 |
PB Ratio | 0.27 | 1.14 | 1.91 | 2.13 | 1.86 | 4.96 |
P/TBV Ratio | 0.27 | 1.15 | 1.92 | 2.13 | 1.88 | 5.03 |
P/OCF Ratio | - | 65.36 | - | - | - | - |
PEG Ratio | - | 94.42 | 94.42 | 94.42 | 94.42 | 94.42 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.50 | 3.74 | 2.38 | 3.05 | 2.39 | 3.49 |
EV/EBITDA Ratio | 11.06 | 28.61 | - | - | 31.87 | 37.17 |
EV/EBIT Ratio | 17.21 | 44.51 | - | - | 146.09 | 136.03 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.23 | 0.18 | 0.85 | 0.78 | 0.44 | 0.69 |
Debt / EBITDA Ratio | 5.50 | 3.79 | - | - | 6.10 | 4.43 |
Net Debt / Equity Ratio | 0.18 | 0.16 | 0.76 | 0.73 | 0.40 | 0.41 |
Net Debt / EBITDA Ratio | 4.40 | 3.41 | -8.64 | -6.57 | 5.58 | 2.64 |
Net Debt / FCF Ratio | -2.13 | -3.32 | -5.12 | -2.86 | -2.49 | -1.99 |
Asset Turnover | 0.25 | 0.31 | 0.44 | 0.40 | 0.59 | 0.69 |
Inventory Turnover | 2.42 | 2.98 | 2.53 | 1.65 | 2.18 | 2.89 |
Quick Ratio | 0.36 | 0.28 | 0.24 | 0.26 | 0.33 | 0.51 |
Current Ratio | 0.76 | 0.64 | 0.50 | 0.82 | 1.01 | 1.03 |
Return on Equity (ROE) | 7.12% | 6.81% | -64.87% | -22.00% | 3.01% | -1.75% |
Return on Assets (ROA) | 1.37% | 1.65% | -3.79% | -4.83% | 0.60% | 1.10% |
Return on Invested Capital (ROIC) | 2.12% | 3.62% | -8.81% | -10.18% | 1.37% | 3.26% |
Return on Capital Employed (ROCE) | 2.10% | 2.40% | -10.40% | -13.30% | 1.30% | 3.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 18.17% | 3.74% | -32.58% | -10.48% | 0.68% | -0.28% |
FCF Yield | -30.96% | -4.20% | -7.80% | -11.94% | -8.69% | -4.18% |
Buyback Yield / Dilution | -19.97% | -19.98% | -4.65% | 9.69% | -10.85% | - |
Total Shareholder Return | -19.96% | -19.98% | -4.65% | 9.69% | -10.85% | - |